Sub-Community 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳立宗 [443/510] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] Siblings 分子與基因醫學研究所 [921/964] 生技與藥物研究所 [830/1008] 生醫工程與奈米醫學研究所 [1214/1334] 免疫醫學研究中心 [224/236] 神經及精神醫學研究中心 [782/804] 細胞及系統醫學研究所 [755/815] 感染症與疫苗研究所 [1541/1618] 群體健康科學研究所 [2870/3000] 國家環境醫學研究所 [1560/1591] 國家蚊媒傳染病防治研究中心 [102/104] 高齡醫學暨健康福祉研究中心 [216/224] 論壇 [2/2] 生醫資源中心 [7/7] 研究生培育合作學程 [188/191] 核心儀器設施中心 [9/9] 病理核心實驗室 [14/14] 實驗動物中心 [8/8] 行政管理部門 [18/18] Community Statistics 近3年內發表的文件:335(13.91%) 含全文筆數:2250(93.40%) 文件下載次數統計 下載大於0次:2250(100.00%) 下載大於100次:2250(100.00%) 檔案下載總次數:1606259(29.97%) 最後更新時間: 2024-11-28 06:18 Top Upload Loading... Top Download Loading... Recent Submissions Pathological response following neo... Registry of genetic alterations of ... Activated single nucleotide mismatc... Taiwan nationwide study of first-li... The effectiveness of virtual passpo... Special Issue "Bioinformatics ... Evaluating a natural language proce... The clinicopathological significanc... Hypoxia in drug resistance and radi... DKK1 as a chemoresistant protein mo...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 226-250 of 2409. (97 Page(s) Totally) << < 5 6 7 8 9 10 11 12 13 14 > >> View [10|25|50] records per page

Date	Title	Relation
2022-10-23	Real-world comparative effectiveness of nivolumab versus pembrolizumab in patients with unresectable hepatocellular carcinoma	Pharmaceutics. 2022 Oct 23;14(11):Article number 2263.
2022-10-22	Vickers hardness value test via multi-task learning convolutional neural networks and image augmentation	Applied Sciences. 2022 Oct 22;12(21):Article number 10820.
2022-10-20	Reprogramming of sentinel lymph node microenvironment during tumor metastasis	Journal of Biomedical Science. 2022 Oct 20;29:Article number 84.
2022-10-11	Upregulated ubiquitin D is a favorable prognostic indicator for rectal cancer patients undergoing preoperative concurrent chemoradiotherapy	OncoTargets and Therapy. 2022 Oct 11;15:1171-1181.
2022-10-10	Prognostic abilities of pre- and post-treatment inflammatory markers in oral squamous cell carcinoma: Stepwise modelling	Medicina. 2022 Oct 10;58(10):Article number 1426.
2022-10	Chronic mechanical irritation enhances the effect of tobacco and alcohol on the risk of oral squamous cell carcinoma: A case-control study in Argentina	Clinical Oral Investigations. 2022 Oct;26(10):6317-6326.
2022-10	The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma	Hepatology International. 2022 Oct;16(5):1137-1149.
2022-10	Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study	Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-10	An integrated microfluidic device for automated detection of cancer cells from bile for cholangiocarcinoma prognosis	MicroTAS 2022 - 26th International Conference on Miniaturized Systems for Chemistry and Life Sciences. 2022 Oct:229-230.
2022-09-26	Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?	Journal of Biomedical Science. 2022 Sep 26;29:Article number 74.
2022-09-21	Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer	International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
2022-09-15	Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin	American Journal of Cancer Research. 2022 Sep 15;12(9):4267-4278.
2022-09-13	UMOD mutations in chronic kidney disease in Taiwan	Biomedicines. 2022 Sep 13;10(9):Article number 2265.
2022-09	Beta-glucan therapy converts the inhibition of myeloid-derived suppressor cells in oral cancer patients	Oral Diseases. 2022 Sep;28(6):1484-149.
2022-09	Neuropsychiatric symptoms and mortality among patients with mild cognitive impairment and dementia due to Alzheimer's disease	Journal of the Formosan Medical Association. 2022 Sep;121(9):1705-1713.
2022-09	Multi-kinase inhibitors for the treatment of asymptomatic radioactive Iodine-refractory differentiated thyroid cancer: Global non-interventional study (RIFTOS MKI)	Thyroid. 2022 Sep;32(9):1059-1068.
2022-09	A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study	European Journal of Cancer. 2022 Sep;173:123-132.
2022-09	High MT2A expression predicts worse prognosis in patients with urothelial carcinoma	Oncology. 2022 Sep;100(9):485-497.
2022-09	Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan	Liver Cancer. 2022 Sep;11(5):426-439.
2022-09	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	Annals of Oncology. 2022 Sep;33(7):S565-S566.
2022-08-28	Injectability, processability, drug loading, and antibacterial activity of gentamicin-impregnated mesoporous bioactive glass composite calcium phosphate bone cement in vitro	Biomimetics. 2022 Aug 28;7(3):Article number 121.
2022-08-07	Selenium yeast and fish oil combination diminishes cancer stem cell traits and reverses cisplatin resistance in A549 sphere cells	Nutrients. 2022 Aug 7;14(15):Article number 3232.
2022-08	STAT3 Inactivation and Induction of Apoptosis Associate With Fluoxetine-inhibited Epithelial-mesenchymal Transition and Growth of Triple-negative Breast Cancer In Vivo	Anticancer Research. 2022 Aug;42(8):3807-3814.
2022-08	IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET/AKT/FOXO3/c-MYC axis	Cell and Bioscience. 2022 Aug;12:Article number 124.

Showing items 226-250 of 2409. (97 Page(s) Totally) << < 5 6 7 8 9 10 11 12 13 14 > >> View [10|25|50] records per page